Dataset Information

Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics, and treatment regimens.

ABSTRACT: The success of antimicrobial treatment is threatened by the evolution of drug resistance. Population genetic models are an important tool in mitigating that threat. However, most such models consider resistance emergence via a single mutational step. Here, we assembled experimental evidence that drug resistance evolution follows two patterns: (i) a single mutation, which provides a large resistance benefit, or (ii) multiple mutations, each conferring a small benefit, which combine to yield high-level resistance. Using stochastic modeling, we then investigated the consequences of these two patterns for treatment failure and population diversity under various treatments. We find that resistance evolution is substantially limited if more than two mutations are required and that the extent of this limitation depends on the combination of drug type and pharmacokinetic profile. Further, if multiple mutations are necessary, adaptive treatment, which only suppresses the bacterial population, delays treatment failure due to resistance for a longer time than aggressive treatment, which aims at eradication.

SUBMITTER: Igler C

PROVIDER: S-EPMC8184216 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics, and treatment regimens.

Igler Claudia C Rolff Jens J Regoes Roland R

eLife 20210518

The success of antimicrobial treatment is threatened by the evolution of drug resistance. Population genetic models are an important tool in mitigating that threat. However, most such models consider resistance emergence via a single mutational step. Here, we assembled experimental evidence that drug resistance evolution follows two patterns: (i) a single mutation, which provides a large resistance benefit, or (ii) multiple mutations, each conferring a small benefit, which combine to yield high- ...[more]

PMID: 34001313

Similar Datasets

Project description:Predicting runoff with precision holds immense importance for flood control, water resource management, and basin ecological dispatch. Deep learning, especially long short-term memory (LSTM) neural networks, has excelled in runoff prediction, often outperforming traditional hydrological models. Recent studies suggest that deep learning models employing the self-attention mechanism, such as Transformer and Informer, can achieve even better results than LSTM. However, research exploring the multi-step runoff prediction capabilities of these novel models across diverse scenarios remains scarce. In this investigation, we introduce a relative location coding-enhanced Informer model, termed Rel-Informer, and compare its performance in rainfall-runoff prediction against the standard Informer, Transformer, and LSTM models. The publicly available CAMELS dataset is utilized for training and validating the models, and four experiments are designed: (1) Individual rainfall-runoff modeling (one model per catchment); (2) Regional rainfall-runoff modeling (one model per region); (3) Fine-tuned regional rainfall-runoff modeling (fine-tuned from Experiment 2); (4) Large-scale rainfall-runoff modeling for ungauged catchments (one model for all catchments). The findings reveal that Rel-Informer consistently performs better than the other models, particularly in short-term runoff predictions (1-3 days ahead). Although regional modeling is less precise than individual modeling, it significantly benefits from fine-tuning. The large-scale regional Rel-Informer model effectively predicts runoff in ungauged catchments, showcasing its potential for widespread runoff prediction. This study underscores the influence of hydrological characteristics, such as snowmelt and baseflow indices, on prediction accuracy. In conclusion, the Rel-Informer model, enhanced with improved relative position encoding, emerges as a promising tool for runoff forecasting, especially in data-rich catchments.

Project description:BackgroundTreatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and causes substantial toxicity. The newer anti-tuberculosis drugs, bedaquiline and delamanid, and repurposed drugs clofazimine and linezolid, show great promise for combination in shorter, less-toxic, and effective regimens. To date, there has been no randomized, internally and concurrently controlled trial of a shorter, all-oral regimen comprising these newer and repurposed drugs sufficiently powered to produce results for pre-XDR TB patients.MethodsendTB-Q is a phase III, multi-country, randomized, controlled, parallel, open-label clinical trial evaluating the efficacy and safety of a treatment strategy for patients with pre-XDR TB. Study participants are randomized 2:1 to experimental or control arms, respectively. The experimental arm contains bedaquiline, linezolid, clofazimine, and delamanid. The control comprises the contemporaneous WHO standard of care for pre-XDR TB. Experimental arm duration is determined by a composite of smear microscopy and chest radiographic imaging at baseline and re-evaluated at 6 months using sputum culture results: participants with less extensive disease receive 6 months and participants with more extensive disease receive 9 months of treatment. Randomization is stratified by country and by participant extent-of-TB-disease phenotype defined according to screening/baseline characteristics. Study participation lasts up to 104 weeks post randomization. The primary objective is to assess whether the efficacy of experimental regimens at 73 weeks is non-inferior to that of the control. A sample size of 324 participants across 2 arms affords at least 80% power to show the non-inferiority, with a one-sided alpha of 0.025 and a non-inferiority margin of 12%, against the control in both modified intention-to-treat and per-protocol populations.DiscussionThis internally controlled study of shortened treatment for pre-XDR TB will provide urgently needed data and evidence for clinical and policy decision-making around the treatment of pre-XDR TB with a four-drug, all-oral, shortened regimen.Trial registrationClinicalTrials.Gov NCT03896685. Registered on 1 April 2018; the record was last updated for study protocol version 4.3 on 17 March 2023.

Dataset Information

Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics, and treatment regimens.

Publications

Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics, and treatment regimens.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets